Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Preventive Effects of Evista on Bone Fractures in Osteoporosis Reported
June 17, 2002
- We Are at Exciting Crossroads in History: Mr Hassan at PhRMA
June 17, 2002
- Matsumotokiyoshi: Record-high Sales of \256 Bil., Profits of \6.6 Bil. Posted
June 17, 2002
- Eli Lilly's Teriparatide Effective against Severe Osteoporosis
June 17, 2002
- 94 Drugs in Development for Children: PhRMA Survey
June 17, 2002
- BULLETIN
June 17, 2002
- Ohki: Consolidated Sales Increase by 4.1% to \69.7 Bil.
June 17, 2002
- Clinical Trial Results for Eli Lilly's New ED Drug Reported
June 17, 2002
- GSK Publishes Review of Its Commitment to Society, Environment
June 17, 2002
- BUSINESS NEWS IN BRIEF
June 17, 2002
- OTC NEW IN BRIEF
June 17, 2002
- Taxotere-based Chemotherapy Improves Breast Cancer Survival
June 17, 2002
- Lilly's Drotrecogin Prolongs Survival of Severe Sepsis Patients
June 17, 2002
- Website NEWS
June 17, 2002
- Hitachi Medical to Commercialize Regenerative Tooth
June 17, 2002
- Zoledronate Effective against Bone Metastases from Prostate Cancer
June 17, 2002
- Quality of Pharmacoeconomic Research Poor: GL Needed
June 17, 2002
- Sendai Citizens' Demand Rejected: Suit over Withdrawn Drugs
June 17, 2002
- Kodak: Interfaces for Medical Image Networks
June 17, 2002
- Major Wholesalers Post Double-digit Rises in Sales, Profits
June 17, 2002
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…